Study guide
2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery
PEBC Pharmacist Evaluating Examination Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Introduction & The Canadian Pharmacy Practice Landscape
1.1 PEBC EE Blueprint, Format, Scoring, and IPG Certification Pathway 1.2 The Canadian Healthcare System, Canada Health Act, and Drug Regulation 1.3 Canadian Pharmacy Regulatory Framework, NAPRA Standards, and Professional Legislation
2 Chapter 2: Pharmaceutics & Drug Delivery Systems
2.1 Physicochemical Principles, Solubility, Ionization, and Stability 2.2 Solid Dosage Forms, Formulation Science, and Modified-Release Technologies 2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery 2.4 Sterile Product Principles, Parenteral Delivery, and Biopharmaceuticals 2.5 Pharmaceutical Quality: GMP, Stability Testing, and Bioequivalence
3 Chapter 3: Biopharmaceutics & Clinical Pharmacokinetics
3.1 Drug Absorption, Distribution, Metabolism, and Elimination (ADME) 3.2 Bioavailability, Bioequivalence, and Biopharmaceutics Classification System (BCS) 3.3 Pharmacokinetic Modeling, Parameters, and Dosing Calculations 3.4 Therapeutic Drug Monitoring (TDM) and Clinical Application
4 Chapter 4: Pharmacology, Toxicology & Pharmacogenetics
4.1 Autonomic and Central Nervous System Pharmacology 4.2 Cardiovascular, Renal, and Endocrine Pharmacology 4.3 Clinical Toxicology, Overdose Management, and Antidotes 4.4 Biologics, Biosimilars, and Pharmacogenetics
5 Chapter 5: Pathophysiology & Clinical Assessment
5.1 Clinical Laboratory Diagnostics, Biomarkers, and Vital Signs 5.2 Cardiovascular and Respiratory Pathophysiology 5.3 Endocrine, Renal, and Gastrointestinal Pathophysiology 5.4 Neurologic, Psychiatric, and Musculoskeletal Pathophysiology 5.5 Physical Assessment and Point-of-Care Testing
6 Chapter 6: Pharmacotherapy & Minor Ailments
6.1 Cardiovascular Pharmacotherapy & Evidence-Based Guidelines 6.2 Endocrine and Metabolic Pharmacotherapy 6.3 Infectious Diseases and Antimicrobial Stewardship 6.4 Neurologic, Psychiatric, and Pain Management Therapeutics 6.5 Minor Ailment Prescribing and Nonprescription Therapy 6.6 Respiratory Pharmacotherapy: Asthma, COPD, and Inhaled Therapy 6.7 Gastrointestinal and Hepatic Pharmacotherapy 6.8 Renal, Fluid, and Electrolyte Therapeutics 6.9 Musculoskeletal and Rheumatologic Pharmacotherapy 6.10 Dermatologic, Ophthalmic, and Ear-Nose-Throat Pharmacotherapy 6.11 Hematologic, Immunologic, and Oncology Supportive Care 6.12 Women's Health, Men's Health, and Urologic Therapeutics 6.13 Nutrition, Natural Health Products, and Complementary Medicine
7 Chapter 7: Special Populations & Applied Therapeutics
7.1 Geriatric Pharmacotherapy and Deprescribing 7.2 Pediatric and Neonatal Pharmacotherapy 7.3 Perinatal Pharmacotherapy: Pregnancy and Lactation 7.4 Dosage Adjustments in Renal and Hepatic Impairment
8 Chapter 8: Prescription Processing, Calculations & Compounding
8.1 Prescription Processing, Verification, and Drug Therapy Problem Management 8.2 Pharmaceutical Calculations and Clinical Math 8.3 Non-Sterile Compounding and NAPRA Standards 8.4 Sterile and Hazardous Compounding under NAPRA Standards 8.5 Advanced Calculations: Infusion Rates, Parenteral Nutrition, and Renal Estimation
9 Chapter 9: Health Equity, Indigenous Health & Pharmacy Bioethics
9.1 Social Determinants of Health and Health Equity 9.2 Indigenous Health, Cultural Safety, and Humility 9.3 Pharmacy Bioethics, Informed Consent, and Professional Boundaries 9.4 Health Promotion, Disease Prevention, and Public Health
10 Chapter 10: Evidence Appraisal, Safety & Practice Management
10.1 Biostatistics and Critical Appraisal of Clinical Literature 10.2 Pharmacoeconomics and Pharmacoepidemiology 10.3 Medication Safety, Incident Analysis, and Quality Improvement 10.4 Pharmacy Operations, Cold-Chain Management, and Emergency Preparedness 10.5 Drug Information and Evidence-Based Decision Making 10.6 Pharmacovigilance and Adverse Drug Reaction Reporting in Canada
11 Chapter 11: Patient Care Process, Communication & Collaborative Practice
11.1 The Patient Care Process: Assessment, Care Plans, and Follow-Up 11.2 Patient and Caregiver Communication, Education, and Health Literacy 11.3 Motivational Interviewing and Shared Decision-Making 11.4 Intra- and Interprofessional Collaborative Care
12 Chapter 12: Medication Administration, Devices & Expanded Scope
12.1 Injection and Vaccine Administration Technique 12.2 Immunization Schedules, Vaccine Selection, and Travel Health 12.3 Home Medical Devices and Device Technique Coaching 12.4 Expanded Scope: Adapting, Renewing, Initiating, and Medication Reconciliation
13 Chapter 13: Pharmacy Management, Finance & Practice Leadership
13.1 Human Resources, Leadership, and Change Management 13.2 Financial Management, Drug Plans, and Marketing 13.3 Quality Improvement, Risk Management, and Workplace Safety
2.3 Liquid and Semisolid Dosage Forms, Dispersions, and Topical Delivery
Key Takeaways Explain This Topic AI
Syrups achieve self-preservation through high sucrose concentrations ( 65 − 85 % 65-85\% 65 − 85% w/v) that depress water activity, whereas elixirs utilize ethanol ( 5 − 40 % 5-40\% 5 − 40% ) as a cosolvent.
Stokes' law governs suspension sedimentation velocity, which is reduced by particle micronization and increasing vehicle viscosity using pseudoplastic polymers.
Flocculated suspensions form loose, porous particle networks that settle rapidly but resist irreversible caking and redisperse readily upon agitation.
The Hydrophilic-Lipophilic Balance (HLB) guides emulsifier selection; low HLB values ( 3 − 6 3-6 3 − 6 ) favor W/O emulsions, whereas high HLB values ( 8 − 16 8-16 8 − 16 ) favor O/W emulsions.
External heat exposure or skin barrier disruption significantly accelerates transdermal drug flux, creating life-threatening overdose risks with high-potency patches.
Last updated: August 2026
Monophasic Liquid Dosage Forms and Cosolvency
Monophasic liquid dosage forms represent true homogeneous molecular dispersions containing one or more chemical components dissolved in a single liquid phase. They provide rapid absorption, dosing flexibility for pediatric and geriatric patients, and immediate bioavailability.
Syrups, Elixirs, and Liquid Vehicles
Syrups: Concentrated aqueous solutions of sucrose or other sugars.
USP Syrup (Simple Syrup) contains 85 % 85\% 85% w/v (or 65 % 65\% 65% w/w ) sucrose in purified water, with a specific gravity of 1.313 1.313 1.313 . At this high osmotic concentration, the water activity ( a w a_w a w ) is depressed below 0.85 0.85 0.85 , preventing microbial proliferation without added chemical preservatives. Dilution of simple syrup requires adding antimicrobial preservatives (e.g., sodium benzoate, methylparaben).
Diabetic Syrups: Formulated with non-glycemic cellulose polymers (e.g., hydroxyethylcellulose, sodium carboxymethylcellulose) and artificial sweeteners (e.g., sucralose, saccharin sodium).
Elixirs: Clear, sweetened, flavored hydroalcoholic solutions intended for oral use.
Ethanol Concentration: Varies from 5 % 5\% 5% to 40 % 40\% 40% v/v . Ethanol functions as a vital cosolvent to maintain poorly water-soluble organic compounds in solution.
Preservation: Formulations containing > 15 % > 15\% > 15% to 20 % 20\% 20% ethanol are self-preserving against bacterial and fungal growth.
Clinical Cautions: Alcohol-containing elixirs must be avoided in pediatric populations and patients taking medications that induce disulfiram-like reactions (e.g., metronidazole, sulfonylureas) or severe central nervous system depression.
Cosolvent Systems: Blending water with water-miscible organic solvents (e.g., propylene glycol, glycerin, polyethylene glycol 400) lowers the dielectric constant of the solvent blend, increasing the solubility of non-polar drug molecules by several orders of magnitude.
Coarse Dispersions: Pharmaceutical Suspensions
A suspension is a coarse two-phase dispersion in which insoluble solid drug particles (dispersed phase, typically > 0.5 μ m > 0.5\ \mu\text{m} > 0.5 μ m ) are homogeneously distributed throughout a liquid vehicle (continuous phase).
Thermodynamic Instability and Stokes' Law
Suspensions are inherently thermodynamically unstable because milling particles into fine powders dramatically increases interfacial surface area ( Δ A \Delta A Δ A ), creating positive interfacial free energy ( Δ G = γ S L ⋅ Δ A \Delta G = \gamma_{SL} \cdot \Delta A Δ G = γ S L ⋅ Δ A , where γ S L \gamma_{SL} γ S L is solid-liquid interfacial tension). The system naturally minimizes free energy by particle agglomeration.
Particle sedimentation velocity under gravity is described by Stokes' Law : v = d 2 ⋅ ( ρ p − ρ m ) ⋅ g 18 ⋅ η v = \frac{d^2 \cdot (\rho_p - \rho_m) \cdot g}{18 \cdot \eta} v = 18 ⋅ η d 2 ⋅ ( ρ p − ρ m ) ⋅ g
Where:
v v v is the sedimentation velocity ( cm / s \text{cm}/\text{s} cm / s ).
d d d is the particle diameter ( cm \text{cm} cm ).
ρ p \rho_p ρ p and ρ m \rho_m ρ m are the densities of the solid particle and liquid medium ( g / cm 3 \text{g}/\text{cm}^3 g / cm 3 ).
g g g is the gravitational acceleration constant ( 980 cm / s 2 980\text{ cm}/\text{s}^2 980 cm / s 2 ).
η \eta η is the dynamic viscosity of the medium ( Poise \text{Poise} Poise or Pa ⋅ s \text{Pa}\cdot\text{s} Pa ⋅ s ).
Formulation Interventions to Retard Sedimentation:
Micronization: Because d d d is squared, halving the particle diameter reduces sedimentation rate by a factor of 4.
Viscosity Enhancement: Suspending agents (e.g., xanthan gum, sodium carboxymethylcellulose, carbomers) increase η \eta η . Ideal suspending agents exhibit pseudoplastic (shear-thinning) and thixotropic rheology: high viscosity at rest to prevent settling on the shelf, but low viscosity upon shaking to facilitate pouring.
Flocculated vs. Deflocculated Suspensions
Property Deflocculated Suspension Flocculated Suspension
Particle State Individual, separate particles Loose, porous clusters ("flocs") held by weak van der Waals forces
Zeta Potential High ( > ∣ 30 ∣ mV > \vert30\vert\text{ mV} > ∣30∣ mV ), high electrostatic repulsion Low (typically − 20 to − 30 mV -20\text{ to }-30\text{ mV} − 20 to − 30 mV ), controlled repulsion
Sedimentation Rate Slow (particles settle individually) Rapid (flocs settle as a collective network)
Sediment Volume ( F F F ) Low ( F ≪ 1 F \ll 1 F ≪ 1 ), compact sediment High ( F ≈ 1 F \approx 1 F ≈ 1 ), voluminous porous sediment
Caking Tendency Severe caking: Small particles fill interstitial voids under gravity, forming an irreversible, hard cake that cannot be resuspended Resists caking: Loose structure prevents close packing; easily redispersed upon gentle shaking
Supernatant Appearance Cloudy/turbid during settling Clear supernatant with distinct boundary Suspension Stability Strategy:
Deflocculated Particles --> Slow settling, BUT forms a cement-like, irreversible CAKE.
- Flocculated Particles --> Fast settling, BUT easily REDISPERSED upon gentle shaking! (Preferred)
- Emulsions and the HLB System
An emulsion is a thermodynamically unstable dispersion of two immiscible liquid phases (typically oil and water) stabilized by an amphiphilic emulsifying agent (surfactant).
Emulsion Types and Identification Tests
Oil-in-Water (O/W): Oil droplets dispersed in continuous water phase. Washable with water, non-greasy, suitable for oral administration and cosmetically elegant creams.
Water-in-Oil (W/O): Water droplets dispersed in continuous oil phase. Emollient, occlusive, non-water-washable, protective.
Identification Tests:
Dilution Test: An emulsion can only be diluted with its continuous phase (O/W dilutes freely with water; W/O separates).
Conductivity Test: O/W emulsions conduct electric current due to dissolved aqueous electrolytes; W/O emulsions do not conduct.
Dye Solubility: Water-soluble dyes (e.g., amaranth) color O/W emulsions; oil-soluble dyes (e.g., Sudan III) color W/O systems.
The Hydrophilic-Lipophilic Balance (HLB) System
The Griffin HLB scale ranges from 1 1 1 to 20 20 20 , categorizing surfactants by their relative hydrophilic versus lipophilic nature:
HLB 3 to 6 3\text{ to }6 3 to 6 (Lipophilic): Favors Water-in-Oil (W/O) emulsions (e.g., Sorbitan monooleate / Span 80 , HLB 4.3 4.3 4.3 ).
HLB 8 to 16 8\text{ to }16 8 to 16 (Hydrophilic): Favors Oil-in-Water (O/W) emulsions (e.g., Polysorbate 80 / Tween 80 , HLB 15.0 15.0 15.0 ).
HLB Calculation for Surfactant Blends: HLB blend = ( f A ⋅ HLB A ) + ( f B ⋅ HLB B ) \text{HLB}_{\text{blend}} = (f_A \cdot \text{HLB}_A) + (f_B \cdot \text{HLB}_B) HLB blend = ( f A ⋅ HLB A ) + ( f B ⋅ HLB B )
Where f A f_A f A and f B f_B f B are the weight fractions of surfactants A and B ( f A + f B = 1.0 f_A + f_B = 1.0 f A + f B = 1.0 ).
Physical Instability Pathways in Emulsions
Creaming / Sedimentation: Upward movement of oil droplets (lower density) or downward settling of water droplets. Reversible upon shaking.
Flocculation: Reversible aggregation of droplets without rupture of the interfacial surfactant film.
Coalescence: Irreversible fusion of smaller droplets into larger droplets due to interfacial film breakdown.
Breaking (Cracking): Complete, irreversible phase separation into distinct bulk oil and water layers. Re-shaking cannot restore the emulsion.
Phase Inversion: Transition of an O/W emulsion to a W/O emulsion (or vice versa), triggered by temperature changes or addition of divalent electrolytes (e.g., adding Ca 2 + \text{Ca}^{2+} Ca 2 + converts a sodium soap O/W emulsion to a calcium soap W/O emulsion).
Semisolid Dosage Forms and Topical/Transdermal Delivery
Semisolid preparations are applied to the skin or mucous membranes for local therapeutic action or systemic transdermal absorption.
USP Ointment Base Classification
Base Class Composition Water Content / Washability Occlusivity & Properties
Hydrocarbon (Oleaginous) White petrolatum, yellow ointment, paraffin Anhydrous, immiscible, non-washable Highly occlusive (maximizes hydration and skin penetration), greasy, emollient
Absorption Bases Hydrophilic petrolatum, anhydrous lanolin, Aquaphor Anhydrous, non-washable, absorbs water Can absorb aqueous solutions to form W/O emulsions; moderately occlusive
Water-Removable Bases (O/W Creams) Hydrophilic ointment, vanishing cream Contains water ( > 50 % > 50\% > 50% ), water-washable Non-greasy, cosmetically elegant, absorbs serous discharges in acute weeping dermatitis
Water-Soluble Bases Polyethylene glycol (PEG) ointment Greaseless, completely water-soluble Non-occlusive, water-washable, softens upon adding aqueous solutions; used for non-aqueous drugs
Percutaneous Absorption Kinetics and Transdermal Drug Delivery
The primary barrier to percutaneous absorption is the stratum corneum (the outermost keratinized epidermal layer structured as "bricks and mortar").
Fick's First Law of Transdermal Diffusion: J = D ⋅ K ⋅ Δ C h J = \frac{D \cdot K \cdot \Delta C}{h} J = h D ⋅ K ⋅ Δ C
Where:
J J J is the steady-state transdermal drug flux ( mass / ( area ⋅ time ) \text{mass}/(\text{area}\cdot\text{time}) mass / ( area ⋅ time ) ).
D D D is the diffusion coefficient of the drug within the stratum corneum.
K K K is the stratum corneum / vehicle partition coefficient.
Δ C \Delta C Δ C is the drug concentration gradient across the skin.
h h h is the barrier thickness of the stratum corneum.
Transdermal Patch Architectures and Clinical Safety
Reservoir Patches: Drug is contained within a liquid reservoir separated from the skin by a rate-controlling polymeric membrane. Critical Safety Rule: Reservoir patches must NEVER be cut , as cutting ruptures the rate-controlling membrane, causing catastrophic dose dumping and fatal toxicity.
Matrix / Drug-in-Adhesive Patches: Drug is homogeneously dissolved or suspended directly within the adhesive matrix layer. The release rate is governed by the matrix polymer and skin barrier.
Heat and Transdermal Toxicity: Elevated body temperature (fever) or external heat sources (electric heating pads, saunas, hot tubs) induce cutaneous vasodilation, elevate skin temperature, and increase the diffusion coefficient D D D . This causes massive surges in drug flux (e.g., transdermal fentanyl flux can increase by > 100 − 300 % > 100-300\% > 100 − 300% , precipitating fatal respiratory arrest).
MRI Safety: Patches with metallic backings (e.g., aluminum backing in certain clonidine, fentanyl, or scopolamine patches) can cause severe local skin burns during magnetic resonance imaging (MRI) and must be removed prior to scanning.